Molecular Typing (SSOP)
Abacavir hypersensitivity has been shown to be associated with HLA-B*5701. The FDA has issued a recommendation that all patients should be screened for the HLA-B*5701 allele before starting or restarting treatment with Abacavir (Ziagen) or Abacavir-containing medications. Treatment with an Abacavir-containing regimen is not recommended for HLA-B*5701 positive patients.
Interpretive report will indicate presence or absence of HLA-B*5701.
- HLA Class I One Locus (High Resolution)
- TISSUE TYPING
- B5701 Antigen
- Abacavir Sensitivity
- HLA B*5701
- HLA REPORT
Collect specimen in sufficient yellow top (ACD) solution A tubes early in the day. Send intact specimen at room temperature. Do not refrigerate or freeze.
Serious and sometimes fatal hypersensitivity reactions caused by Abacavir therapy are significantly more common in patients with the HLA-B*5701 allele. Abacavir hypersensitivity is a multi-organ syndrome characterized by two or more clinical signs or symptoms that can include fever, rash, gastrointestinal symptoms, respiratory symptoms and constitutional symptoms. Clinicians should discontinue Abacavir therapy permanently if the patient becomes seriously ill and hypersensitivity cannot be ruled out, regardless of HLA-B*5701 status.